A Phase I, Open-label Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of a Single Dose of Balcinrenone/Dapagliflozin in Healthy Chinese Participants
Latest Information Update: 24 Oct 2024
Price :
$35 *
At a glance
- Drugs Balcinrenone/Dapagliflozin (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 24 Oct 2024 New trial record